UniProtKB/SwissProt variant VAR

Variant information

Variant position:

836

The position of the amino-acid change on the UniProtKB canonical protein sequence.

Type of variant:

US

The variants are classified into three categories: LP/P, LB/B and US.

LP/P: likely pathogenic or pathogenic.
LB/B: likely benign or benign.
US: uncertain significance

Residue change:

From Isoleucine (I) to Methionine (M) at position 836 (I836M, p.Ile836Met).

Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.

Physico-chemical properties:

Similar physico-chemical property. Both residues are medium size and hydrophobic.

The physico-chemical property of the reference and variant residues and the change implicated.

BLOSUM score:

1

The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:

Lowest score: -4 (low probability of substitution).
Highest score: 11 (high probability of substitution).

More information can be found on the following page

Variant description:

In acute lymphoblastic leukemia patients; somatic mutation.

Any additional useful information about the variant.

Other resources:

Links to websites of interest for the variant.

Variant rs121913232 [ dbSNP | Ensembl ]

Sequence information

Variant position:

836

The position of the amino-acid change on the UniProtKB canonical protein sequence.

Protein sequence length:

993

The length of the canonical sequence.

Location on the sequence:

NVLVTHGKVVKICDFGLARD I MSDSNYVVRGNARLPVKWMA

The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.

Residue conservation:

The multiple alignment of the region surrounding the variant against various orthologous sequences.

Human                         NVLVTHGKVVKICDFGLARDIMSDSNYVVRGNARLPVKWMA

Mouse                         NVLVTHGKVVKICDFGLARDILSDSSYVVRGNARLPVKWMA

Sequence annotation in neighborhood:

The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:

Type: the type of sequence feature.
Positions: endpoints of the sequence feature.
Description: contains additional information about the feature.

Type	Positions	Description
Chain	27 – 993	Receptor-type tyrosine-protein kinase FLT3
Topological domain	564 – 993	Cytoplasmic
Domain	610 – 943	Protein kinase
Modified residue	842 – 842	Phosphotyrosine; by autocatalysis
Alternative sequence	807 – 847	Missing. In isoform 2.
Helix	836 – 838

Literature citations

FLT3 mutations in the activation loop of tyrosine kinase domain are frequently found in infant ALL with MLL rearrangements and pediatric ALL with hyperdiploidy.
Taketani T.; Taki T.; Sugita K.; Furuichi Y.; Ishii E.; Hanada R.; Tsuchida M.; Sugita K.; Ida K.; Hayashi Y.;
Blood 103:1085-1088(2004)
Cited for: VARIANTS GLU-835; HIS-835; TYR-835; ILE-836 DEL AND MET-836; FUNCTION IN ACTIVATION OF STAT5A AND/OR STAT5B; PHOSPHORYLATION; INVOLVEMENT IN AML;

UniProtKB/Swiss-Prot variant pages

UniProtKB/Swiss-Prot P36888: Variant p.Ile836Met